The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55 novel drugs. The top 20 companies on the ledger changed from their 2017 ranking- leading to major ups & downs in the positions. Johnson and Johnson again proved to be the among the highest rank in 2018 generating revenue of $81.5B. Our team at PharmaShots has compiled a list of top 20 pharma companies based on their 2018 total revenue.

Total Revenue: $13.45B                                                               Total Employees: ~7-800     

Pharma Segment Revenue: $10.86B                                     Non-Pharma Segment Revenue: $2.56B

Founded Year:  1978                                                                      Headquarter: Massachusetts- United States

Market Cap: ~$46B                                                                         Stock Exchange: NASDAQ

Biogen is a global biopharmaceutical company focusing on neurology with a broad portfolio including Tecfidera- Avonex- Plegridy- Tysabri and Fampyra. Biogen has expanded its business in 2018- with the acquisition of BIIB100 & BIIB110 candidates from Karyopharm and AliveGen respectively and further collaborated with Pfizer for BIIB100. The company has expanded its partnership with Ionis Pharmaceuticals with ten year agreement for the development of antisense oligonucleotide (ASO) drug candidates in neurological diseases. Biogen has also entered into a research collaboration with C4 Therapeutics (C4T) for its novel protein degradation platform.

Total Revenue: $15.42B                                                                 Total Employees: ~16-962

Pharma Segment Revenue: $15.26B                                       Non-Pharma Segment Revenue: $0.01B

Founded Year: 1986                                                                         Headquarter: New Jersey- United States

Market Cap: ~$66B                                                                          Stock Exchange: NASDAQ

Celgene is an integrated global biopharmaceutical company focused on developing therapies for cancer & inflammatory diseases. Celgene's numerous key products are in P-III trials including Revlimid- Otezla- evaluated in patients with r/r follicular or marginal zone lymphoma & Behcet's disease respectively. In 2019- Celgene has been acquired by BMS for $74B.

Total Revenue: $15.78B                                                                  Total Employees: ~17-000

Pharma Segment Revenue: $15.42B                                         Non-Pharma Segment Revenue: $0.36B

Founded Year: 1950                                                                          Headquarter: Dublin- Ireland

Market Cap: ~$48B                                                                            Stock Exchange: NYSE

Allergan is an Irish pharmaceutical company focused on developing & commercializing pharmaceuticals- devices- biologic- surgical and regenerative medicine for the people around the globe. Allergan didn't has much difference in revenue in comparison to its 2017 revenue. Allergan?s blockbuster products- Botox cosmetic- Botox therapeutic- Vraylar- and Juvederm added nearly $1B to its 2018 revenue.

Total Revenue: $16.90B                                                               Total Employees: ~43-202

Pharma Segment Revenue: $16.67B                                     Non-Pharma Segment Revenue: $0.23B

Founded Year: 1989                                                                       Headquarter: Bagsværd, Denmark

Market Cap: ~$97B                                                                         Stock Exchange: Copenhagen

Novo Nordisk is a global healthcare company focusing on therapies for Diabetes- Obesity- Hemophilia and growth disorders. 2018 was a progressive year for Novo Nordisk as it reached its target with the launch of Ozempic for the treatment of Type-2 Diabetes. Novo Nordisk is expected to increase its sales by 2-5% in 2019.

Total Revenue: $18.854B                                                             Total Employees: ~45-000

Pharma Segment Revenue: $17.48B                                     Non-Pharma Segment Revenue: $1.36B

Founded Year: 1944                                                                       Headquarter: Petah Tikva- Israel

Market Cap: ~$16B                                                                         Stock Exchange: NYSE 

Teva Pharmaceutical is an Israeli multinational pharmaceutical company focused on generics- specialty medicines and biopharmaceuticals. Company's specialty portfolio includes Capaxone for multiple sclerosis- Ajovy for the treatment of migraine & Austedo for movement disorder. Teva's biosimilars (developed by Celltrion) were approved by the FDA in 2018- including Truxima & Herzuma biosimilar to rituximab & trastuzumab respectively.

Total Revenue: $22.09B                                                                Total Employees: ~50-000

Pharma Segment Revenue: $21.04B                                      Non-Pharma Segment Revenue: $1.04B

Founded Year:  1999                                                                       Headquarter: Cambridge- United Kingdom

Market Cap: ~$105.8B                                                                    Stock Exchange: LSE

AstraZeneca is a global- biopharmaceutical company focusing on Oncology- Respiratory- Neurology- Autoimmune and other therapy areas. In Dec'18 AstraZeneca and Merck's Lynparza (olaparib) received FDA's approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer and signed an immune-oncology clinical collaboration with AVEO oncology. In May-18 AstraZeneca has also received FDA's approval for its Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalemia in adults.

Total Revenue: $22.12B                                                                 Total Employees: ~11-000

Pharma Segment Revenue: $21.67B                                      Non-Pharma Segment Revenue: $0.45B

Founded Year: 1987                                                                        Headquarter: California- United States

Market Cap: ~$84B                                                                          Stock Exchange: NASDAQ

Gilead Sciences is a research-based biopharmaceutical company with a broad portfolio of drugs. Biktarvy- Descovy- Odefsey- Genvoya- Stribild are approved in the US & EU for HIV infection in adults. Biktarvy received FDA's approval in Feb'18 for the treatment-naive HIV-1 infected in adults.

Total Revenue: $22.56B                                                                  Total Employees: ~23-300

Pharma Segment Revenue: $22.56B                                        Non-Pharma Segment Revenue: Nil

Founded Year: 1989                                                                          Headquarter: New York- United States

Market Cap: ~$75B                                                                            Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on Oncology- Cardiovascular- Immunology and Fibrosis. Its blockbuster drugs- Opdivo (nivolumab) for cancer & Eliquis as anticoagulant positioned BMS in the top 20 global pharma companies. BMS remained to be in the highlights- with its acquisition of Celgene in early 2019. The acquisition will boost up BMS' pipeline in Oncology- Immunology- Inflammation & Cardiology.

Total Revenue: $23.74B                                                               Total Employees: ~21-000

Pharma Segment Revenue: $22.53B                                     Non-Pharma Segment Revenue: $1.2B

Founded Year: 1980                                                                      Headquarter: California- United States

Market Cap: ~$120B                                                                     Stock Exchange: NASDAQ

Amgen is one of the leading biotechnology company developing novel therapies focused on Cardiology- Oncology- Neurology- Nephrology- and Inflammatory diseases. The company's total revenue increased by 7%- leading to a total increment of $6.2B. The company recently launched products Repatha (evolocumab)- Prolia (denosumab)- Kyprolis (carfilzomib) and Xgeva (denosumab) which presented a double- digit growth.

Total Revenue: $24.55B                                                                 Total Employees:  ~38-000

Pharma Segment Revenue: $22.93B                                      Non-Pharma Segment Revenue: $1.62B

Founded Year: 1901                                                                        Headquarter: Indiana- United States 

Market Cap: ~$139B                                                                       Stock Exchange: NYSE

Eli Lilly and Company is a global pharmaceutical firm focused on developing therapies in the areas of diabetes- lung cancer- osteoporosis & men's health. In Sep'18- Lilly's animal health business Elanco completed its IPO on NYSE. In 2018- it had collaborated with Hydra Biosciences- AC immune to develop immune & neurodegenerativetherapies respectively. The FDA granted fast track designation to Lilly's Olumiant for SLE in Dec-18.

Total Revenue: $30.57B                                                                Total Employees: ~103-000

Pharma Segment Revenue: $9.43B                                         Non-Pharma Segment Revenue: $21.14B

Founded Year: 1900                                                                        Headquarter: Illinois- United States

Market Cap: ~$130B                                                                       Stock Exchange: NYSE

Abbott Laboratories is an American healthcare company with a broad pipeline of generics- diagnostic- natural products- Cardiovascular and Neuromodulation products. In 2018- Abbott received FDA's approval for the Advisor HD grid mapping catheter- sensor enabled MitraClip- a heart valve repair device- HeartMate 3 left ventricular assist device (LVAD)- XIENCE Sierra drug eluting stent system

Total Revenue: $32.73B                                                                 Total Employees: ~30-000   

Pharma Segment Revenue: $32.73B                                       Non-Pharma Segment Revenue: Nil

Founded Year: 1900                                                                        Headquarter: Illinois- United States 

Market Cap: ~$122B                                                                       Stock Exchange: NYSE 

AbbVie is a global- research-based biopharmaceutical company that develops therapies majorly for Chronic autoimmune diseases- Oncology- Virology with additional targets like cystic fibrosis and Women's health. In Oct-18 Health Canada approved AbbVie's Orilissa (elagolix) for pain associated with endometriosis. Its blockbuster product Humira (adalimumab) is a biologic therapy and is approved in multiple countries globally. In Dec,18- AbbVie pact a deal with Lupin to develop novel therapies for cancer.